Interactive Features

Test Your Knowledge

Quiz: Should Pembrolizumab Be New Standard of Care for MSI-H/dMMR Metastatic CRC?

06/04/2020

True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?

True or False: Pembrolizumab...

06/04/2020

Oncology

Test Your Knowledge

Quiz: Improved PFS with TAS-102 plus Bevacizumab Versus Monotherapy for mCRC?

05/22/2020

True or false: TAS-102 plus bevacizumab yields clinically significant PFS improvement over TAS-102 monotherapy in patients with metastatic colorectal cancer.

True or false: TAS-102 plus...

05/22/2020

Oncology

Test Your Knowledge

Quiz: Is Long-Term Imatinib Therapy Effective at Delaying GIST Recurrence?

05/06/2020

True or false: 5-year adjuvant imatinib therapy is not effective at controlling recurrence rates in patients with previously resected gastrointestinal stromal tumors (GIST).

True or false: 5-year adjuvant...

05/06/2020

Oncology

Test Your Knowledge

Quiz: Which Therapy is Preferred for mCRC After Progression?

05/04/2020

True or false: Upfront FOLFOXIRI plus bevacizumab reintroduced after progression is preferable to chemotherapy doublets for metastatic colorectal cancer.

True or false: Upfront FOLFOXIRI...

05/04/2020

Oncology

Test Your Knowledge

Quiz: Elevated GGT's Impact on OS in Patients With Metastatic CRPC

04/30/2020

True or false: Elevated GGT prognosticates longer OS in patients with metastatic castration-resistant prostate cancer receiving enzalutamide.

True or false: Elevated GGT...

04/30/2020

Oncology

Test Your Knowledge

Quiz: Adding Sporadic Oxaliplatin to This Regimen Promising for CRC

04/02/2020

Combining which chemotherapy regimen with intermittent oxaliplatin could be as effective as adjuvant chemo postsurgery for colon cancer?

Combining which chemotherapy...

04/02/2020

Oncology

Test Your Knowledge

Quiz: Acupuncture for Peripheral Neuropathy?

04/02/2020

True or false: In a randomized trial of patients with solid tumors, acupuncture was found to reduce symptoms of chemotherapy-induced peripheral neuropathy.

True or false: In a randomized...

04/02/2020

Oncology

Test Your Knowledge

Quiz: Any Benefit to Continuing Full Induction Regimen in Metastatic CRC?

01/17/2020

True or False: There is no benefit to continuing a full induction regimen until progression without a period of observation or maintenance therapy in patients with metastatic colorectal cancer.

True or False: There is no...

01/17/2020

Oncology

Test Your Knowledge

Quiz: Can We Predict Benefit of Preoperative Therapy for Sigmoid Colon Cancer?

01/03/2020

True or False: CT scans may predict whether patients with sigmoid colon cancer will benefit from preoperative therapy.

True or False: CT scans may...

01/03/2020

Oncology

Test Your Knowledge

Quiz: Is 3-Month Capecitabine Plus Oxaliplatin Appropriate for CRC?

10/28/2019

True or False: For patients with CRC, a 3-month chemo regimen of capecitabine plus oxaliplatin may be the most appropriate treatment option, especially among those with low-risk disease.

True or False: For patients with...

10/28/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology